Home › Acute Myeloid Leukemia › Pennsylvania

Pag-aaral pangklinika para sa Acute Myeloid Leukemia sa Pennsylvania

45 pag-aaral para sa Acute Myeloid Leukemia ang naghahanap ng mga kalahok sa mga site sa Pennsylvania.

Mga Lungsod sa Pennsylvania

Opisyal na teksto ng pag-aaral (English)

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Thomas Jefferson University Hospital, Philadelphia

Nagre-recruitPhase 2

Edad 60 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07437950

Assessment of Geriatric Evaluations Impact on New AML Guidance

Abramson Cancer Center at University of Pennsylvania, Philadelphia

Nagre-recruitObservasyonal na pag-aaral

Edad 50 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05909501

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Lehigh Valley Hospital-Cedar Crest, Allentown
Lehigh Valley Hospital - Muhlenberg, Bethlehem
Geisinger Medical Center, Danville
at 7 pa

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo

Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Children's Hospital of Philadelphia, Philadelphia

Nagre-recruitObservasyonal na pag-aaral

Edad 0 hanggang 38 · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06131801

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Lehigh Valley Hospital-Cedar Crest, Allentown
Geisinger Medical Center, Danville
Penn State Milton S Hershey Medical Center, Hershey
at 4 pa

Nagre-recruitPhase 2

Edad 18 hanggang 59 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Thomas Jefferson University, Philadelphia
Fox Chase Cancer Center, Philadelphia
University of Pittsburgh Medical Center, Pittsburgh

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Lehigh Valley Hospital-Cedar Crest, Allentown
Geisinger Medical Center, Danville
Penn State Milton S Hershey Medical Center, Hershey
at 6 pa

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Children's Hospital of Philadelphia, Philadelphia
Children's Hospital of Pittsburgh of UPMC, Pittsburgh

Nagre-recruitPhase 1

Hanggang edad 21 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Lehigh Valley Hospital-Cedar Crest, Allentown
Geisinger Medical Center, Danville
Penn State Milton S Hershey Medical Center, Hershey
at 4 pa

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Geisinger Medical Center, Danville
Thomas Jefferson University Hospital, Philadelphia
UPMC Hillman Cancer Center, Pittsburgh
at 1 pa

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Lehigh Valley Hospital-Cedar Crest, Allentown
Geisinger Medical Center, Danville
Penn State Milton S Hershey Medical Center, Hershey
at 6 pa

Nagre-recruitPhase 2

Edad 18 hanggang 59 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Lehigh Valley Hospital-Cedar Crest, Allentown
Geisinger Medical Center, Danville
Penn State Children's Hospital, Hershey
at 3 pa

Nagre-recruitPhase 3

6 Months – 21 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

University of Pennsylvania, Philadelphia

Nagre-recruitPhase 1/2

30 Days · Lahat ng kasarian · Na-update Set 16, 2026 · NCT04065399

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Spoknwrd Clinical Trials Inc., Easton

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06824168

A Study of BGB-11417 in Participants With Myeloid Malignancies

Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT04771130

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

UPENN Perelman Center for Advanced Medicine, Philadelphia

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06846606

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Geisinger Medical Center, Danville
Children's Hospital of Philadelphia, Philadelphia
Children's Hospital of Pittsburgh of UPMC, Pittsburgh

Nagre-recruitPhase 3

Edad 1 hanggang 25 · Lahat ng kasarian · Na-update Set 4, 2026 · NCT07022678

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Cancer Care Associates of York, York

Nagre-recruitObservasyonal na pag-aaral

Edad 0 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07154823

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

US-Pittsburgh PA-PITT, Pittsburgh

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06652438

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

US-Pittsburgh PA-PITT, Pittsburgh

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 1, 2026 · NCT07223814

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Lehigh Valley Hospital-Cedar Crest, Allentown
Geisinger Medical Center, Danville
Penn State Children's Hospital, Hershey
at 3 pa

Nagre-recruitPhase 1/2

Hanggang edad 22 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Children's Hospital of Philadelphia, Philadelphia

Nagre-recruitPhase 3

29 Days – 21 Years · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

University of Pennsylvania, Philadelphia

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT07007312

Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

UMPC Hillman Cancer Center, Pittsburgh

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT07565220

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

UPMC Hillman Cancer Center, Pittsburgh

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT06529731

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

University of Pennsylvania, Philadelphia

Nagre-recruitPhase 2/3

Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT06788756

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Children's Hospital of Philadelphia, Philadelphia

Nagre-recruitPhase 1

Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT06177067

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

Penn Medicine Abramson Cancer Center, Philadelphia

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 10, 2026 · NCT05442216

CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML

University of Pennsylvania, Philadelphia

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 9, 2026 · NCT05945849

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

Children's Hospital of Philadelphia, Philadelphia

Nagre-recruit

Hanggang edad 25 · Lahat ng kasarian · Na-update Hul 8, 2026 · NCT03810196

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

Children's Hospital of Philadelphia, Philadelphia

Nagre-recruitPhase 1

Edad 0 hanggang 29 · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT07464951

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Penn State Milton S. Hershey Cancer Center, Hershey
Children's Hospital of Philadelphia, Philadelphia
Children's Hospital of Pittsburgh, Pittsburgh
at 3 pa

Nagre-recruitObservasyonal na pag-aaral

Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Penn Medicine - Abramson Cancer Center Perelman, Philadelphia

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Hun 24, 2026 · NCT04068597

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

University of Pennsylvania, Philadelphia

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update May 14, 2026 · NCT06222580

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Pennsylvania State University Hershey Medical Center, Hershey

Nagre-recruitPhase 1

Hanggang edad 21 · Lahat ng kasarian · Na-update Abr 22, 2026 · NCT05101551

Massage Impact on Sleep in Pediatric Oncology

Children's Hospital of Philadelphia, Philadelphia

Nagre-recruit

Edad 12 hanggang 21 · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT06892158

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Sidney Kimmel Comprehensive Cancer Center, Philadelphia
Allegheny Health Network, Pittsburgh

Nagre-recruitPhase 1/2

Edad 12 pataas · Lahat ng kasarian · Na-update Mar 24, 2026 · NCT04988555

Phase IB/II of CPX-351 for Relapse Prevention in AML

University of Pennsylvania, Philadelphia

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Mar 23, 2026 · NCT04990102

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Thomas Jefferson University Hospital, Philadelphia

Nagre-recruitPhase 1

Edad 12 pataas · Lahat ng kasarian · Na-update Mar 16, 2026 · NCT06994676

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Hospital of the University of Pennsylvania, Philadelphia

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT05735184

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.